Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 6 | Journal of Biomedical Science

Fig. 6

From: Gemcitabine resistance by CITED4 upregulation via the regulation of BIRC2 expression in pancreatic cancer

Fig. 6

Knockout of CITED4 decreases pancreatic tumor growth in an orthotopic mouse model. A Schematic of the experimental procedure. PANC-1 (PBS, n = 5; GEM, n = 6), CITED4 knockout PANC-1 #1 (PBS, n = 8; GEM, n = 9) or #3 (PBS, n = 7; GEM, n = 8) cell were implanted to pancreas of BALB/c nude mice. After 2 weeks, the mice were treated with GEM (50 mg/kg) twice per week for 6 weeks. B Tumors were detected in mice using in vivo bioluminescence imaging (left), and bioluminescent intensities were quantified (right). Two-way ANOVA was used for statistical analysis. C Macroscopic images of each tumor (scale bar, 1 cm). Red circles indicate complete regression. D Average of tumor weight. E Schematic representation of the roles of CITED4 in GEM-resistant PC. *P < 0.05 and ***P < 0.001

Back to article page